SBI Healthcare Opportunities Fund - Direct Plan -Growth
SBI Funds Management Private Limited · Direct Plan · Growth
Fund overview
0.50% on or before 15D, Nil after 15D
Returns & rankings
| Period | Fund Returns | Category Avg. | Rank | VS Category |
|---|---|---|---|---|
| … | ||||
Green = fund outperformed the category average for that period; red = underperformed. Periods under 1 year always show absolute (non-annualised) returns. Past performance does not guarantee future returns.
Return calculator
One-time investment
₹5,000
| Over the past | Total investment | Would've become | Returns |
|---|---|---|---|
| 1 Year | ₹5,000 | ₹5,872 | +872 |
| 3 Years | ₹5,000 | ₹8,097 | +3,097 |
| 5 Years | ₹5,000 | ₹11,165 | +6,165 |
Calculated using the fund's annualised return since inception (17.4% p.a.) as period-wise historical returns aren't available in the current feed. Actual returns fluctuate and are not guaranteed. Mutual fund investments are subject to market risks.
Holdings
36 securitiesTop 10 holdings make up 51.6% of the portfolio.
| Security | Sector | Market Cap | Weight |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | Pharmaceuticals & Biotechnology | Large Cap | 11.14% |
| Divi'S Laboratories Ltd | Pharmaceuticals & Biotechnology | Large Cap | 7.91% |
| TREPS | Cash/Deposits/Margins/Treps/Repo/Swaps | — | 6.42% |
| AMI Organics Ltd | Pharmaceuticals & Biotechnology | Small Cap | 5.03% |
| Apollo Hospitals Enterprises Ltd | Healthcare Services | Large Cap | 4.45% |
| Torrent Pharmaceuticals Ltd | Pharmaceuticals & Biotechnology | Large Cap | 4.42% |
| Cipla Ltd | Pharmaceuticals & Biotechnology | Large Cap | 4.40% |
| Laurus Labs Ltd | Pharmaceuticals & Biotechnology | Mid Cap | 4.05% |
| Max Healthcare Institute Ltd | Healthcare Services | Mid Cap | 3.80% |
| Aurobindo Pharma Ltd | Pharmaceuticals & Biotechnology | Mid Cap | 3.42% |
Portfolio Allocation
Equity / Debt / Cash
Total Value
₹5,870 Cr
Market Cap Split
Total Value
100%
Equity sector allocation
Total Value
₹5,608 Cr
Debt sector allocation
Total Value
₹3 Cr
Allocation By Credit Quality (Debt)
Exit load, stamp duty & tax
01-Jan-13
0.50% on or before 15D, Nil after 15D
0.005% (from July 1st, 2020)
Taxation depends on the fund category and holding period. Consult the scheme document or a tax advisor for details.
Risk & Performance Ratios (1Y)
| Standard Deviation | 13.99% |
| Beta | 0.85 |
| Sharpe Ratio | 3.02 |
| Sortino Ratio | -0.07 |
| Treynor Ratio | 0.50 |
| Jensen's Alpha | 4.60 |
| Information Ratio | -0.07 |
| R-Squared | 93.91% |
| Max Drawdown | -4.07% |
| Upside Capture | 94.83% |
| Downside Capture | 84.80% |
Fund management
Scheme Details
Investment objective
To Provide The Investors With The Opportunity Of Long-Term Capital Appreciation By Investing In A Diversified Portfolio Of Equity And Equity Related Securities In Healthcare Space.
Fund house
SBI Funds Management Private Limited
Frequently asked questions
What is the NAV of SBI Healthcare Opportunities Fund - Direct Plan -Growth?
The NAV of SBI Healthcare Opportunities Fund - Direct Plan -Growth is ₹553.17 as of 21 Oct 2026. NAV is updated at the end of every trading day.
How much expense ratio is charged by SBI Healthcare Opportunities Fund - Direct Plan -Growth?
The expense ratio charged by SBI Healthcare Opportunities Fund - Direct Plan -Growth is 1.01%.
What is the Min. SIP of SBI Healthcare Opportunities Fund - Direct Plan -Growth?
The minimum SIP investment in SBI Healthcare Opportunities Fund - Direct Plan -Growth is ₹500 per month.
What is the Min. Lumpsum of SBI Healthcare Opportunities Fund - Direct Plan -Growth?
The minimum lumpsum investment in SBI Healthcare Opportunities Fund - Direct Plan -Growth is ₹5,000.
What is the Exit Load of SBI Healthcare Opportunities Fund - Direct Plan -Growth?
The exit load for SBI Healthcare Opportunities Fund - Direct Plan -Growth is: 0.50% on or before 15D, Nil after 15D
.svg){kind=small}